Evidence map›Paper›PMID 30328970›Full record

ArticleRevista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)

Efficacy of adjunctive Garcinia mangostana Linn (mangosteen) pericarp for bipolar depression: study protocol for a proof-of-concept trial.

Melanie M Ashton, Michael Berk, Chee H Ng, Malcolm Hopwood, Seetal Dodd, Alyna Turner, Ellie Brown, Felice N Jacka, Susan M Cotton, Jon-Paul Khoo and 9 more

Open access · diamondAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. The efficacy of adjunctiveThe British journal of psychiatry : the journal of mental science · 2025
    Trial
  2. Trial
  3. AdjunctiveCanadian journal of psychiatry. Revue canadienne de psychiatrie · 2021
    Trial
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 9 institutions in 2 countries.

Melanie M AshtonDeakin University, Innovation in Mental and Physical Health and Clinical Treatment (IMPACT) Strategic Research Centre, School of Medicine, Barwon Health, Geelong, Australia.
Michael BerkDeakin University, Innovation in Mental and Physical Health and Clinical Treatment (IMPACT) Strategic Research Centre, School of Medicine, Barwon Health, Geelong, Australia.
Chee H NgDepartment of Psychiatry, The Melbourne Clinic, University of Melbourne, Richmond, Australia.
Malcolm HopwoodFlorey Institute for Neuroscience and Mental Health, University of Melbourne, Parkville, Australia.
Seetal DoddDeakin University, Innovation in Mental and Physical Health and Clinical Treatment (IMPACT) Strategic Research Centre, School of Medicine, Barwon Health, Geelong, Australia.
Alyna TurnerDeakin University, Innovation in Mental and Physical Health and Clinical Treatment (IMPACT) Strategic Research Centre, School of Medicine, Barwon Health, Geelong, Australia.
Ellie BrownDeakin University, Innovation in Mental and Physical Health and Clinical Treatment (IMPACT) Strategic Research Centre, School of Medicine, Barwon Health, Geelong, Australia.
Felice N JackaDeakin University, Innovation in Mental and Physical Health and Clinical Treatment (IMPACT) Strategic Research Centre, School of Medicine, Barwon Health, Geelong, Australia.
Susan M CottonOrygen, National Centre of Excellence in Youth Mental Health, Parkville, Australia.
Jon-Paul KhooDeakin University, Innovation in Mental and Physical Health and Clinical Treatment (IMPACT) Strategic Research Centre, School of Medicine, Barwon Health, Geelong, Australia.
Mary Lou ChattertonCentre for Population Health Research, Deakin Health Economics, Deakin University, Geelong, Australia.
Bianca E KavanaghDeakin University, Innovation in Mental and Physical Health and Clinical Treatment (IMPACT) Strategic Research Centre, School of Medicine, Barwon Health, Geelong, Australia.
Sarah E NadjidaiDepartment of Psychiatry, The Melbourne Clinic, University of Melbourne, Richmond, Australia.
Samantha L Lo MonacoDeakin University, Innovation in Mental and Physical Health and Clinical Treatment (IMPACT) Strategic Research Centre, School of Medicine, Barwon Health, Geelong, Australia.
Brian H HarveyCenter of Excellence for Pharmaceutical Sciences, School of Pharmacy, North-West University, Potchefstroom, South Africa.
Jerome SarrisDepartment of Psychiatry, The Melbourne Clinic, University of Melbourne, Richmond, Australia.
Gin S MalhiAcademic Department of Psychiatry, Northern Sydney Local Health District, St. Leonards, Australia.
Nathan L DowlingDepartment of Psychiatry, The Melbourne Clinic, University of Melbourne, Richmond, Australia.
Olivia M DeanDeakin University, Innovation in Mental and Physical Health and Clinical Treatment (IMPACT) Strategic Research Centre, School of Medicine, Barwon Health, Geelong, Australia.
Deakin University · AUMelbourne Clinic · AUBarwon Health · AUThe Royal Melbourne Hospital · AUUniversity of Melbourne · AUBlack Dog Institute · AUFlorey Institute of Neuroscience and Mental Health · AUNorthern Sydney Local Health District · AUNorth-West University · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveBipolar depression is characterized by neurobiological features including perturbed oxidative biology, reduction in antioxidant levels, and a concomitant rise in oxidative stress markers. Bipolar depression manifests systemic inflammation, mitochondrial dysfunction, and changes in brain growth factors. The depressive phase of the disorder is the most common and responds the least to conventional treatments. Garcinia mangostana Linn, commonly known as mangosteen, is a tropical fruit. The pericarp's properties may reduce oxidative stress and inflammation and improve neurogenesis, making mangosteen pericarp a promising add-on therapy for bipolar depression.

methodsParticipants will receive 24 weeks of either 1,000 mg mangosteen pericarp or placebo per day, in addition to their usual treatment. The primary outcome is change in severity of mood symptoms, measured using the Montgomery-Åsberg Depression Rating Scale (MADRS), over the treatment phase. Secondary outcomes include global psychopathology, quality of life, functioning, substance use, cognition, safety, biological data, and cost-effectiveness. A follow-up interview will be conducted 4 weeks post-treatment.

conclusionThe findings of this study may have implications for improving treatment outcomes for those with bipolar disorder and may contribute to our understanding of the pathophysiology of bipolar depression. CLINICAL

trial registrationAustralian and New Zealand Clinical Trial Registry, ACTRN12616000028404.

Indexed as

AntioxidantsAustraliaBipolar DisorderClinical Trials as TopicDepressive DisorderFruitGarcinia mangostanaHumansPlacebosQuality of LifeAntioxidantsPlacebos

Identifiers

PMID30328970
PMCPMC6794139
OpenAlexW2897766883

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.